前列腺癌中的T细胞衔接器
前列腺癌因免疫微环境「冷」而免疫治疗疗效有限,T细胞衔接器(TCE)通过结合T细胞CD3与肿瘤抗原诱导T细胞杀伤癌细胞,在经治转移性去势抵抗性前列腺癌中显示前列腺特异性抗原和影像学应答,但免疫原性、抗药抗体及细胞因子释放综合征等毒性阻碍其进入临床实践。
要点
- TCE通过结合T细胞CD3与肿瘤抗原诱导T细胞杀伤癌细胞,为前列腺癌提供新机制治疗选择。
- 在经治转移性去势抵抗性前列腺癌中,TCE显示前列腺特异性抗原和影像学应答。
- TCE面临免疫原性、抗药抗体影响血清药物暴露及细胞因子释放综合征等免疫相关不良事件挑战。
核心结论
- TCE在前列腺癌中显示有前景的抗肿瘤活性,但仍面临免疫原性、抗药抗体和毒性等挑战,阻碍其进入临床实践。
研究设计与样本
- 综述,总结多项在经治转移性去势抵抗性前列腺癌患者中探索TCE的研究及正在进行的评估新型TCE单药或联合方案的试验。
主要发现
- TCE通过结合T细胞CD3受体与恶性细胞表达的特定肿瘤抗原,诱导T细胞介导的癌细胞杀伤。
- 在经治转移性去势抵抗性前列腺癌中,TCE显示有前景的抗肿瘤活性,包括前列腺特异性抗原和影像学应答。
- TCE的免疫原性和抗药抗体产生可能影响其血清药物暴露。
- TCE的毒性特征包括细胞因子释放综合征和其他免疫相关不良事件。
临床怎么用
- 为改善疗效并等待正在进行试验的结果,联合方案、更早治疗线应用和生物标志物驱动的选择可能发挥作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 receptor on T cells and a specific tumor antigen expressed on malignant cells, represent a promising therapeutic option. Multiple studies have explored the use of TCEs in previously treated patients with metastatic castration-resistant prostate cancer, and several ongoing trials are currently assessing novel TCEs either as single agents or in combinatorial regimens with molecules with a distinct mechanism of action (eg, androgen receptor pathway inhibitors and other immune-targeting agents). Although TCEs have shown promising antitumor activity with prostate-specific antigen and radiographic responses, they still face considerable challenges that prevent their implementation into clinical practice. These include their immunogenicity and the development of antidrug antibodies, which could impact their serum drug exposure, as well as their toxicity profile involving cytokine release syndrome and other immune-related adverse events. To improve their efficacy and pending the results of ongoing trials, there could be a role for combinatorial regimens, administration in earlier lines of therapy, and biomarker-driven selection.
引用
- Hage Chehade C, Ozay ZI, Ostrowski M, et al. T-cell Engagers in Prostate Cancer. Eur Urol. 2025. PMID: 40074645. doi:10.1016/j.eururo.2025.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。